+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 54 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating a study medicine called MK-1045 in adults with systemic lupus erythematosus SLE or rheumatoid arthritis RA. This phase 1 clinical trial aims to learn about the safety and how well people tolerate MK-1045 when given at different dose levels. The study is sponsored by Merck Sharp & Dohme LLC and focuses on treatment outcomes for these autoimmune conditions. Participants will receive MK-1045 through intravenous IV infusion in varying ways depending on their study group. Some will get a single IV dose at different dose levels, while others will receive three step-up doses over a 3-week interval, progressing from a prime dose to a target dose. The study includes dose escalation panels and an optional dose expansion phase for further evaluation. During the study, participants will be monitored for adverse events up to 52 weeks. Researchers will assess the number of participants experiencing side effects or discontinuing the drug due to side effects. Blood tests will measure MK-1045 levels and the effect on peripheral B cell counts at specific times. This detailed monitoring helps understand the drugs safety, pharmacokinetics, and pharmacodynamics throughout the trial duration.

Age: 18Years - 75YearsAll GendersPhase 1
21 locations
E

Actively Recruiting

Researchers are evaluating the safety, optimal dose, and effectiveness of a combination treatment involving BNT323 trastuzumab pamirtecan and BNT327 pumitamig in people with advanced breast cancer. This includes patients with hormone receptor-positive or negative, HER2-positive, HER2-low, HER2-ultralow, HER2-null breast cancer, or triple-negative breast cancer. The study is a Phase III, multi-site, open-label trial designed to find the best dose and assess the treatments effects in these groups. The study has two parts. Part 1 involves dose escalation where participants with chemotherapy-pretreated advanced breast cancer receive various dose levels of BNT323 plus BNT327 to determine the recommended Phase 2 dose. Part 2 includes dose optimization and exploratory groups, beginning after Part 1s completion. In Part 2 Cohort 1, participants are randomized into four arms to receive either the combination at the recommended dose, the combination at another dose, BNT323 alone, or BNT327 alone. Other cohorts receive the recommended dose without randomization. Participants will undergo treatment cycles with intravenous infusions of the study drugs and be monitored for safety, side effects, and tumor response for up to 36 months. Assessments include tracking dose-limiting toxicities, adverse events, tumor scans, and response rates. Safety monitoring continues up to 90 days after the last dose. The study aims to provide detailed information on the best dose, safety, and potential benefits of these treatments for advanced breast cancer.

Age: 18Years +All GendersPhase 1Phase 2
81 locations
T

Actively Recruiting

Researchers are investigating a combination therapy of BNT326 and pumitamig for adults with advanced or metastatic non-small cell lung cancer NSCLC that has either relapsed, progressed, or is treatment-nafve. The study includes multiple parts to find the best dose levels, assess safety and tolerability, and evaluate how well the therapy works to shrink tumors in this patient population. The trial is open-label and conducted across multiple sites, focusing on participants with confirmed advanced NSCLC where no curative treatment is available. The study consists of three parts Part 1 focuses on finding safe dose combinations of BNT326 with pumitamig Part 2a expands the dose evaluation to examine preliminary effectiveness and safety and Part 2b randomizes participants to optimize dosing and assess the contribution of each therapy component. Participants with prior treatment and those who are treatment-nafve are enrolled in different cohorts. Treatment is administered via intravenous infusion, and dose levels for Part 2b are determined based on earlier results. Participants undergo a screening period before starting treatment, which can continue for up to 24 months or until disease progression or unacceptable side effects occur. Follow-up periods monitor safety, efficacy, and long-term survival, with total involvement expected to last about 36 months unless ongoing benefit warrants extended treatment. Researchers evaluate dose-limiting toxicities, adverse events, tumor response rates, progression-free survival, and pharmacokinetics to understand treatment effects and participant outcomes.

Age: 18Years +All GendersPhase 1Phase 2
86 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of oral AP1189 combined with methotrexate in adults with early rheumatoid arthritis who have not previously been treated with disease-modifying anti-rheumatic drugs DMARDs. This phase II, randomized, double-blind, placebo-controlled study aims to understand how different doses of AP1189 40, 70, or 100 mg impact disease activity and inflammation over 12 weeks in participants with active early rheumatoid arthritis. Participants will be randomly assigned to one of four groups, each receiving daily oral treatment for 12 weeks AP1189 at 40 mg, 70 mg, or 100 mg doses alongside methotrexate, or a placebo alongside methotrexate. The study compares the effects of these treatments on rheumatoid arthritis symptoms and inflammation to determine the best dose of AP1189 when combined with methotrexate. During the study, participants will attend scheduled visits for assessments including joint evaluations, blood tests for inflammation markers such as C-reactive protein CRP, and other safety monitoring. Researchers will measure changes in the Disease Activity Score 28 DAS28-CRP at 12 weeks to evaluate treatment impact. Participants will be monitored closely for safety and tolerability throughout the trial period, which lasts about 12 weeks.

Age: 18Years +All GendersPhase 2
11 locations
O

Actively Recruiting

Researchers are studying the safety and effectiveness of a drug called tacabrutideg for people with B-cell malignancies, a type of cancer that affects white blood cells. These cancers include various forms such as chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma, and others. The study aims to find the best dose of tacabrutideg and evaluate how well it works in shrinking or eliminating these cancers. The study has two parts first, a dose escalation phase where different doses of tacabrutideg are tested to find a recommended dose that is safe and tolerable. Then, an expansion phase enrolls more participants to further assess the safety and effectiveness of the selected dose or doses. Tacabrutideg is given orally. The study includes multiple groups of participants with different types of B-cell malignancies, including some specific cohorts like Japanese participants and those who have not previously received certain kinase inhibitors. Participants will visit clinics regularly over about three years for treatment, health checks, blood tests, tumor imaging, and other assessments. Researchers will monitor side effects, measure cancer response, and collect blood samples to study how the drug behaves in the body. The main outcomes include safety, identifying the best dose, and overall cancer response rates. The study is open label, so both participants and doctors know the treatment given.

Age: 18Years +All GendersPhase 1Phase 2
114 locations
M

Actively Recruiting

Researchers are evaluating the efficacy and safety of duvakitug in people with moderately to severely active Crohns Disease through a multicenter, randomized, double-blind, placebo-controlled Phase 3 maintenance study. The study includes a 40-week pivotal maintenance sub-study followed by a 240-week open-label extension sub-study, with a total duration of up to 286 weeks. Participants must have previously responded to treatment and completed endoscopy in a prior study phase. Participants receive subcutaneous injections of duvakitug or placebo according to the study protocol during the maintenance period. Those who complete the maintenance sub-study may continue in the open-label extension sub-study for longer-term treatment and monitoring. The treatment duration can be up to 280 weeks, including both study periods, with a total of up to 43 on-site visits planned. Throughout the trial, participants attend regular visits for assessments including clinical remission measured by the Crohns Disease Activity Index CDAI, endoscopic response, and patient-reported outcomes. Safety is monitored by tracking adverse events and antidrug antibody development. After treatment, participants have a 45-day follow-up visit. The study evaluates outcomes at Week 40 and continues monitoring throughout the extension period.

Age: 16Years - 80YearsAll GendersPhase 3
109 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of duvakitug in people with moderately to severely active Ulcerative Colitis UC. This Phase 3, multicenter, randomized, double-blind, placebo-controlled maintenance study aims to understand how well duvakitug works to maintain clinical remission and improve symptoms in participants with UC. The trial is sponsored by Sanofi and includes a large, diverse participant group aged 16 to 80 years. Participants receive subcutaneous injections of either one of three doses of duvakitug or a placebo following the study protocol. The study consists of two main periods a 40-week Pivotal Maintenance Sub-Study and a 240-week Open-Label Extension OLE Sub-Study. Those who do not join the OLE will complete a 45-day follow-up after the maintenance phase. Across both periods, participants may have up to 32 on-site visits to monitor treatment and health status. During the study, participants will undergo various assessments including endoscopy, clinical response evaluations, and symptom scoring by modified Mayo Score. Researchers will monitor clinical remission, endoscopic and histologic improvements, corticosteroid use, fatigue, abdominal pain, quality of life, and hospitalization incidence. Safety will be closely tracked through adverse event reporting and measurement of drug concentration and immune response. The total participation duration can be up to 286 weeks, allowing long-term monitoring of duvakitugs effects.

Age: 16Years - 80YearsAll GendersPhase 3
171 locations
P

Actively Recruiting

Researchers are conducting a Phase 1, first-in-human study to evaluate JADE201 in people with Rheumatoid Arthritis. The study aims to assess the safety, tolerability, and how the body processes the drug compared to a placebo. This randomized, double-blind trial will help lay the groundwork for future research of JADE201 in autoimmune diseases. Participants will receive a single ascending dose of JADE201 or placebo through a subcutaneous injection. The study is designed with multiple cohorts, each including six participants. JADE201 is given as a sterile solution under the skin. The trial will take place across multiple sites and is placebo-controlled to compare responses. Participants will be monitored from Day 1 through 36 weeks for safety and tolerability. Researchers will collect data on how the drug is absorbed, distributed, and eliminated in the body. Throughout the study, participants will undergo scheduled visits, lab tests, and other assessments. The study includes inpatient stays and requires adherence to treatment plans and lifestyle guidelines. The total participation may last up to 36 weeks.

Age: 18Years - 70YearsAll GendersPhase 1
8 locations
P

Actively Recruiting

Researchers are investigating CRB-701, an antibody-drug conjugate targeting nectin-4, in adult patients with advanced solid tumors that express this protein. This three-part, open-label Phase 12 trial aims to determine a safe and effective dose of CRB-701 and to understand which cancers might respond to this treatment. The study explores safety, pharmacokinetics, and efficacy to guide future cancer therapies. Participants will receive CRB-701 through intravenous infusion over 30 minutes. The trial includes several dosing groups that range from dose escalation to dose optimization, sometimes combined with an anti-PD-1 drug. Part A focuses on escalating doses to find the maximum tolerated dose, Part B tests dose levels alone or with anti-PD-1 to optimize treatment, and Part C explores the recommended dose in multiple tumor cohorts. During the study, participants will attend clinic visits for infusions and undergo blood tests, CT or MRI scans, and other assessments to monitor tumor response and safety. Researchers will measure the safety, tolerability, and objective response rate to evaluate the treatments effect on tumors over periods ranging from 21 days to up to 6 months. The total study duration and monitoring will capture data on efficacy and side effects to support further research.

Age: 18Years +All GendersPhase 1Phase 2
41 locations
R

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of increasing doses of WVE-007, a stereopure siRNA oligonucleotide, given by subcutaneous injection to adults living with overweight or obesity. The study is conducted in two parts Part A, a single ascending dose study in adults with overweight or mild obesity, and Part B, a repeat dose study in adults with obesity, including those with or without Type 2 Diabetes T2D. Part B also includes groups receiving both WVE-007 and tirzepatide to assess combined effects. Participants are randomly assigned to one of several groups receiving different doses of WVE-007 or placebo. Part A includes doses 1 through 5, while Part B evaluates doses 4 through 7 some groups in Part B also receive weekly tirzepatide alongside WVE-007 or placebo. The study uses a triple-blind design to compare the effects of these treatments. The treatment periods last up to 253 days in Part B and 169 days in Part A, with careful dose escalation and monitoring. During the study, participants undergo regular safety assessments to monitor adverse events from the first day through study end. Researchers measure drug levels in plasma and observe changes in serum activin E over time. Participants will have clinical exams, laboratory tests, and pharmacokinetic and pharmacodynamic evaluations. The study runs until December 2027, allowing long-term follow-up of safety and biological effects.

Age: 18Years - 75YearsAll GendersPhase 1Phase 2
7 locations

1-10 of 54

1